82
Pharma & HealthcareStrong Buy
HDFC Pharma And Healthcare
HDFC · Direct–Growth · rank #2 of 19 by Smart Score
Data updated
Trailing returns
1 Year
19.9%
+24.6% vs index
3 Years
28.4%
+19.1% vs index
5 Years
—
Since launch
28.3%
Year-by-year performance
2024
+52.2%+36.6% vs index
2025
+2.4%-5.3% vs index
2026
+19.9%+25.9% vs index
Why this score
HDFC Pharma And Healthcare scores 82/100 — #2 of 19 Pharma & Healthcare fund (Strong Buy). It stands out for 3y return and sharpe ratio — beating 96% of peers on 3y return. It has no major weak spot vs the category.
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
3Y return28.42% · 96th percentile in category
Sharpe ratio1.39 · 97th percentile in category
Sortino ratio2.20 · 97th percentile in category
Alpha10.90 · 91st percentile in category
Fund size3501.37 Cr · 76th percentile in category
1Y return19.94% · 91st percentile in category
Top holdings
1.Divi's Laboratories Ltd9.39%
2.Sun Pharmaceutical Industries Ltd8.28%
3.Alkem Laboratories Ltd4.64%
4.Cipla Ltd4.15%
5.Apollo Hospitals Enterprise Ltd3.69%
38 disclosed equity positions · portfolio as of Sept 2026 · weights are % of total corpus.